trial · primary record
Ublituximab
Relapsing Multiple Sclerosis
| Phase | Phase 2, Phase 3 |
|---|---|
| Status | RECRUITING |
| Sponsor | Unknown |
| Enrolment | 240 |
| Primary completion | 2033-06-30 |
| Primary endpoint | Part A: Area Under the Curve From Week 0 to 24 (AUC0-W24) of Ublituximab |
| Registry ID | NCT07220252 |
Provenance
- Source: ClinicalTrials.gov
- Fetched at: 2026-10-29T14:32:34.513Z
- Licence class: attribution-required
- Verdict: primary-source
- Entity id: NCT07220252
This record is rendered from the AEaH spine. If the source is unreachable the page is not generated.
Same entity, elsewhere in the suite
- Ublituximab · compound